August 30, 2022
Video
Jeffrey Miller, MD, discusses what is next to come following an analysis of GTB-3550.
June 11, 2022
Video
Jeffrey S. Miller, MD, discusses the findings of a study of the Tri-Specific Killer Engager platform for the activation of natural killer cells for the treatment of refractory acute myeloid leukemia and other cancers.